This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Kaiser Aluminum (KALU)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KALUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cipher Mining Inc. (CIFR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CIFRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
by Zacks Equity Research
Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
NVOPositive Net Change ANIPNegative Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs pharmaceuticals
Zacks.com featured highlights QuickLogic, Willdan, Betterware, Modine Manufacturing and ADMA Biologics
by Zacks Equity Research
QuickLogic, Willdan, Betterware, Modine Manufacturing and ADMA Biologics have been highlighted in this Screen of The Week article.
QUIKPositive Net Change WLDNPositive Net Change MODPositive Net Change ADMAPositive Net Change BWMXPositive Net Change
biotechnology
Why Celcuity (CELC) Might Surprise This Earnings Season
by Zacks Equity Research
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CELCPositive Net Change
biotechnology medical
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
by Zacks Equity Research
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
BMYNegative Net Change GERNPositive Net Change PTCTPositive Net Change AXSMPositive Net Change CRNXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Repsol SA (REPYY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
REPYYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Stocks With Recent Price Strength With More Upside Left
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are QUIK, WLDN, BWMX, MOD and ADMA.
QUIKPositive Net Change WLDNPositive Net Change MODPositive Net Change ADMAPositive Net Change BWMXPositive Net Change
auto-tires-trucks biotechnology construction consumer-discretionary tech-stocks
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
PFEPositive Net Change ADMAPositive Net Change FGENPositive Net Change CRDFPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
BMYNegative Net Change ANIPNegative Net Change ADMAPositive Net Change
biotechnology biotechs pharmaceuticals
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
by Zacks Equity Research
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
RHHBYPositive Net Change PTCTPositive Net Change ANIPNegative Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
by Zacks Equity Research
Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
BAYRYPositive Net Change ANIPNegative Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology pharmaceuticals
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
by Zacks Equity Research
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change CRNXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Laird Superfood, Inc. (LSF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LSFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
by Zacks Equity Research
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change HOTHPositive Net Change
biotechnology biotechs medical pharmaceuticals
Time to be "Overweight" Viking Therapeutics
by Andrew Rocco
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
GSPositive Net Change AAPLPositive Net Change NVOPositive Net Change LLYPositive Net Change GOOGLPositive Net Change VKTXPositive Net Change
biotechnology biotechs
How to Find Up-and-Coming Stocks to Buy Right Now
by Benjamin Rains
One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.
IBBPositive Net Change CGONPositive Net Change
biotechnology
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
by Zacks Equity Research
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change FENCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
by Zacks Equity Research
Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change DERMPositive Net Change
biotechnology biotechs medical pharmaceuticals
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
VRTXNegative Net Change HTGCPositive Net Change CRSPPositive Net Change
biotechnology biotechs pharmaceuticals
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
by Zacks Equity Research
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change AQSTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
BMYNegative Net Change JNJPositive Net Change ADMAPositive Net Change
biotechnology biotechs pharmaceuticals
Should You Buy The RealReal (REAL) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
REALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Airgain (AIRG) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AIRGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
by Zacks Equity Research
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change MIRMPositive Net Change
biotechnology biotechs medical pharmaceuticals